CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Inters…
$50.07+3.11%
报价 2026-11-06
市值
$4.86B
EV
$6.26B
PE (TTM)
–
预期 PE
–
52 周区间距高点 -19.1%
$44.34$61.89
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CRSPCRISPR Therapeutics AG | $4.86B | +3.1% | – | -1,534.4% | – | – | – | |
| COGTCogent Biosciences, Inc. | $5.49B | +7.0% | +646.7% | 0% | – | – | – | |
| PTCTPTC Therapeutics, Inc. | $5.47B | -0.4% | -37.6% | 92.4% | – | 33.3x | – | |
| ERASErasca, Inc. | $5.04B | +8.6% | +837.5% | 0% | – | – | – | |
| EWTXEdgewise Therapeutics, Inc. | $4.85B | +15.9% | – | 0% | 4.9x | 4.1x | – | |
| DNTHDianthus Therapeutics, Inc. | $4.81B | +3.6% | -45.5% | 94.3% | – | – | – | |
| TVTXTravere Therapeutics, Inc. | $4.76B | +1.5% | +40.1% | 94.4% | – | 4103.2x | 705.8x | |
| ADPTAdaptive Biotechnologies Corporation | $4.47B | +4.3% | +7.6% | 75.3% | – | – | – | |
| LEGNLegend Biotech Corporation | $4.33B | +3.8% | +39.4% | 55% | – | – | – | |
| 同行中位数 | – | – | +39.4% | 65.1% | 4.9x | 33.3x | 705.8x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。